-
A survey of cell therapy in China
Time of Update: 2018-03-12
In recent two years, with the approval of kit, Juno, Novartis and other companies' products, cell therapy gradually shows a hot state The clinical application of cytotherapy in China is also increasin
-
11 kinds of traditional Chinese medicine protection sold more than one billion! The growth rate of two new products is over 20%
Time of Update: 2018-03-11
In late February, CFDA issued two successive announcements, approving the continued protection of five traditional Chinese medicine protection varieties such as Pianzihuang, and approving five traditi
-
The upsurge of car-t declaration is emerging, and 6 varieties have passed the consistency evaluation
Time of Update: 2018-03-09
Abstract: many car-t therapeutics have been accepted by CDE Four enterprises have submitted the application for the imitation of tenofovir fumarate dipivoxil tablets CFDA has announced the second batc
-
Glaucoma eye drops in drugstores in key cities increased rapidly with an increase rate of 35%
Time of Update: 2018-03-07
March 6 is World Glaucoma Day At present, there are about 67 million glaucoma patients in the world It is estimated that there will be 79.6 million glaucoma patients by 2020, with a blindness rate of
-
What are the strong competitors of domestic generic drugs in 2018?
Time of Update: 2018-03-04
In 2017, the blowout of class 1 new drugs was "not surprising" However, the follow-up of class 1 new drugs is generic drugs In this issue, Xiaobian will lead you to see which generic drugs submitted i
-
Xinda, Hengrui, Haosen and other eight heavyweight products will be launched soon! The turning point of 2018 pharmaceutical companies' stratification is coming
Time of Update: 2018-03-04
Almost all of the eight innovative drugs are heavy bomb drugs, which are independently researched and developed by Chinese innovative drug enterprises, with the leading target internationally, and can
-
In 2018, which new anticancer drugs will be launched in China?
Time of Update: 2018-03-02
Guide reading 2018 has started With the continuous progress of cancer research, we believe that there will be more and more new anti-cancer drugs to meet with patients By referring to the public infor
-
The market of compound penicillin is 24.9 billion, and the injection of triptolide is 62.50%
Time of Update: 2018-02-28
Antibacterials for whole body use are among the top drugs in the pharmaceutical market, with a wide range of clinical applications and a wide variety of characteristics After the "measures for the adm
-
Huahai pharmaceutical industry is in a rage! 11 anda, 7 consistency evaluation varieties
Time of Update: 2018-02-27
Recently, Huahai pharmaceutical released the 2017 performance express The company's operating revenue was 5 billion yuan, an increase of 22% over the previous year, and the net profit attributable to
-
"Report card" of the first batch of trial medical insurance payment antineoplastic drugs in Shanghai: "TiNi" domestic drugs challenge imported drugs
Time of Update: 2018-02-25
On December 29, 2016, Shanghai Municipality issued the notice on the inclusion of some drugs in the payment of medical insurance after centralized purchase in this Municipality for trial implementatio
-
China's innovative drug blowout in 2017! 39 imported drugs are on the market, 174 class 1 new drugs are declared, and new drugs are on the market faster!
Time of Update: 2018-02-25
Recently, GBI health released the 2017 new drug review summary report According to the report data, in 2017, the number of imported drugs approved reached 39, and the number of domestic class 1 new dr
-
Top 10 drugs under research of Fosun medicine
Time of Update: 2018-02-24
It was once said that if Hengrui is China's Pfizer, then Fosun is China's Johnson & Johnson Although this metaphor is not accurate, it can also show that the two companies are following different deve
-
Competition status of non-small cell lung cancer in China: an unexpected "three kill"
Time of Update: 2018-02-23
For the domestic non-small cell lung cancer market, the time has come for the fierce competition among the three countries For Huadan, the next generation of AstraZeneca in China, the smooth access of
-
The priority is to review 56 "new drug listing" applications, 15 of which have been approved. Which one do you like best?
Time of Update: 2018-02-08
Highlights recently, the drug review center of the State Food and Drug Administration (CDE) released the announcement of drug registration applications to be included in the priority review process (t
-
1 billion large varieties + 2.5 billion fundraising! Gan Li Pharmaceuticals breaks through the IPO to fight for the domestic insulin king
Time of Update: 2018-02-06
The wonderful content comes a few days ago, Ganli Pharmaceutical Co., Ltd (hereinafter referred to as: Ganli pharmaceutical) disclosed the prospectus (application draft) on the website of the CSRC, an
-
Injection consistency evaluation, chemical medicine has come, Chinese medicine is approaching! This is bound to be a more difficult life and death match
Time of Update: 2018-02-04
After the consistency evaluation of oral solid preparations, the more influential chemical injection consistency evaluation was formally put on the work schedule by CFDA In 2016, China's injection sca
-
Four over 100 million products and two heavy new drugs. Does this enterprise want to lead the nervous system drug market?
Time of Update: 2018-02-01
Highlights recently, Denmark Lingbei pharmaceutical announced that its innovative drug lesagilan mesylate (trade name: anzilar ®) was officially launched in China Another innovative drug, voltacetin h
-
2017 chemical registration application panoramic perspective, Hengrui, dongyangguang, Zhengda Tianqing and other famous enterprises
Time of Update: 2018-02-01
Highlights: 1 The 10-year development process of chemical drugs has changed from pursuing quantity to pursuing quality in recent years; 2 2018 will be the crucial year for 289 generic drug conformity
-
12 "China class 1" NDA applications worthy of attention in China
Time of Update: 2018-01-31
The research and development of domestic innovative drugs can not only improve the competitiveness of China's pharmaceutical industry in the global scope, but also solve the drug shortage or even "dru
-
Great harvest of monoclonal antibody in 2017! Approved new drug highlights, local enterprise performance, latest R & D trend
Time of Update: 2018-01-24
After more than 30 years of accumulation, monoclonal antibody drugs have become mature in all aspects, from target development to technical improvement, from clinical research to commercialization str
